Twice-daily prophylactic cranial irradiation for patients with limited disease small-cell lung cancer with complete response to chemotherapy and consolidative radiotherapy: Report of a single institutional phase II trial

Aaron Wolfson, Yadvindera Bains, Jiade Lu, Blessing Etuk, Kasi Sridhar, William Raub, Arnold Markoe

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Prophylactic cranial irradiation (PCI) has been demonstrated to significantly reduce the incidence of brain relapse from limited disease small-cell lung cancer (LD SCLC), but concerns about neurologic toxicity remain. The purpose of this report was to update a phase II institutional trial that explored the impact of twice-daily PCI on neurologic toxicity as well as outcome for this group of patients. All eligible subjects had documented complete response to induction chemotherapy and consolidative chest irradiation. The whole brain was treated with twice-daily fractions of 1.5 Gy with megavoltage irradiation to an approximate total dose of 30.0-36.0 Gy. Although not devised as a randomized study, approximately half of the eligible patients declined the protocol enrollment of their own volition and were retrospectively evaluated as a "historical" control group regarding the incidence of brain metastases. Fifteen patients accepted twice-daily PCI, with 12 deferring treatment. Median follow-up was 20 months. Disease-free survival at 2 years was 54% with twice-daily PCI versus 0% without any PCI (p = 0.013). Overall survival at 2 years was 62% with twice-daily PCI versus 23% without PCI (p = 0.032). No statistically significant neurologic deterioration was detected in the PCI group posttreatment. Thus, twice-daily PCI should be considered for patients with LD SCLC who achieve a complete response to chemoirradiation. A multi-institutional randomized trial would be necessary before making definitive recommendations.

Original languageEnglish
Pages (from-to)290-295
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume24
Issue number3
DOIs
StatePublished - Jun 21 2001

Fingerprint

Cranial Irradiation
Small Cell Lung Carcinoma
Radiotherapy
Drug Therapy
Nervous System
Brain
Induction Chemotherapy
Incidence
Disease-Free Survival
Thorax
Neoplasm Metastasis
Recurrence
Control Groups

Keywords

  • Central nervous system toxicity
  • Chemoirradiation
  • Prophylactic cranial irradiation
  • SCLC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{6bf12903803a4170aef3114e4e18b7e9,
title = "Twice-daily prophylactic cranial irradiation for patients with limited disease small-cell lung cancer with complete response to chemotherapy and consolidative radiotherapy: Report of a single institutional phase II trial",
abstract = "Prophylactic cranial irradiation (PCI) has been demonstrated to significantly reduce the incidence of brain relapse from limited disease small-cell lung cancer (LD SCLC), but concerns about neurologic toxicity remain. The purpose of this report was to update a phase II institutional trial that explored the impact of twice-daily PCI on neurologic toxicity as well as outcome for this group of patients. All eligible subjects had documented complete response to induction chemotherapy and consolidative chest irradiation. The whole brain was treated with twice-daily fractions of 1.5 Gy with megavoltage irradiation to an approximate total dose of 30.0-36.0 Gy. Although not devised as a randomized study, approximately half of the eligible patients declined the protocol enrollment of their own volition and were retrospectively evaluated as a {"}historical{"} control group regarding the incidence of brain metastases. Fifteen patients accepted twice-daily PCI, with 12 deferring treatment. Median follow-up was 20 months. Disease-free survival at 2 years was 54{\%} with twice-daily PCI versus 0{\%} without any PCI (p = 0.013). Overall survival at 2 years was 62{\%} with twice-daily PCI versus 23{\%} without PCI (p = 0.032). No statistically significant neurologic deterioration was detected in the PCI group posttreatment. Thus, twice-daily PCI should be considered for patients with LD SCLC who achieve a complete response to chemoirradiation. A multi-institutional randomized trial would be necessary before making definitive recommendations.",
keywords = "Central nervous system toxicity, Chemoirradiation, Prophylactic cranial irradiation, SCLC",
author = "Aaron Wolfson and Yadvindera Bains and Jiade Lu and Blessing Etuk and Kasi Sridhar and William Raub and Arnold Markoe",
year = "2001",
month = "6",
day = "21",
doi = "10.1097/00000421-200106000-00017",
language = "English",
volume = "24",
pages = "290--295",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Twice-daily prophylactic cranial irradiation for patients with limited disease small-cell lung cancer with complete response to chemotherapy and consolidative radiotherapy

T2 - Report of a single institutional phase II trial

AU - Wolfson, Aaron

AU - Bains, Yadvindera

AU - Lu, Jiade

AU - Etuk, Blessing

AU - Sridhar, Kasi

AU - Raub, William

AU - Markoe, Arnold

PY - 2001/6/21

Y1 - 2001/6/21

N2 - Prophylactic cranial irradiation (PCI) has been demonstrated to significantly reduce the incidence of brain relapse from limited disease small-cell lung cancer (LD SCLC), but concerns about neurologic toxicity remain. The purpose of this report was to update a phase II institutional trial that explored the impact of twice-daily PCI on neurologic toxicity as well as outcome for this group of patients. All eligible subjects had documented complete response to induction chemotherapy and consolidative chest irradiation. The whole brain was treated with twice-daily fractions of 1.5 Gy with megavoltage irradiation to an approximate total dose of 30.0-36.0 Gy. Although not devised as a randomized study, approximately half of the eligible patients declined the protocol enrollment of their own volition and were retrospectively evaluated as a "historical" control group regarding the incidence of brain metastases. Fifteen patients accepted twice-daily PCI, with 12 deferring treatment. Median follow-up was 20 months. Disease-free survival at 2 years was 54% with twice-daily PCI versus 0% without any PCI (p = 0.013). Overall survival at 2 years was 62% with twice-daily PCI versus 23% without PCI (p = 0.032). No statistically significant neurologic deterioration was detected in the PCI group posttreatment. Thus, twice-daily PCI should be considered for patients with LD SCLC who achieve a complete response to chemoirradiation. A multi-institutional randomized trial would be necessary before making definitive recommendations.

AB - Prophylactic cranial irradiation (PCI) has been demonstrated to significantly reduce the incidence of brain relapse from limited disease small-cell lung cancer (LD SCLC), but concerns about neurologic toxicity remain. The purpose of this report was to update a phase II institutional trial that explored the impact of twice-daily PCI on neurologic toxicity as well as outcome for this group of patients. All eligible subjects had documented complete response to induction chemotherapy and consolidative chest irradiation. The whole brain was treated with twice-daily fractions of 1.5 Gy with megavoltage irradiation to an approximate total dose of 30.0-36.0 Gy. Although not devised as a randomized study, approximately half of the eligible patients declined the protocol enrollment of their own volition and were retrospectively evaluated as a "historical" control group regarding the incidence of brain metastases. Fifteen patients accepted twice-daily PCI, with 12 deferring treatment. Median follow-up was 20 months. Disease-free survival at 2 years was 54% with twice-daily PCI versus 0% without any PCI (p = 0.013). Overall survival at 2 years was 62% with twice-daily PCI versus 23% without PCI (p = 0.032). No statistically significant neurologic deterioration was detected in the PCI group posttreatment. Thus, twice-daily PCI should be considered for patients with LD SCLC who achieve a complete response to chemoirradiation. A multi-institutional randomized trial would be necessary before making definitive recommendations.

KW - Central nervous system toxicity

KW - Chemoirradiation

KW - Prophylactic cranial irradiation

KW - SCLC

UR - http://www.scopus.com/inward/record.url?scp=0034994380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034994380&partnerID=8YFLogxK

U2 - 10.1097/00000421-200106000-00017

DO - 10.1097/00000421-200106000-00017

M3 - Article

C2 - 11404503

AN - SCOPUS:0034994380

VL - 24

SP - 290

EP - 295

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -